1. The efficacy and tolerability of proteoglycan F in the treatment of knee osteoarthritis: A prospective, randomized, double-blind controlled trial
- Author
-
Huyen Thi Thanh Vu, Huong Thi Thu Nguyen, Thu Thi Hoai Nguyen, Thanh Xuan Nguyen, Tam Ngoc Nguyen, Anh Lan Nguyen, Luong Thi Hong Nguyen, Huyen Thi La, Hien Thi Thu Vu, Quyen Thi Tu Bui, Thu Nguyet Nghiem, Arunasiri Iddamalgoda, Kenichi Ito, Tatsuji Takahashi, Tuyen Danh Le, Thang Pham, and Anh Trung Nguyen
- Subjects
Osteoarthritis ,Knee ,Proteoglycan ,Effective ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective: To identify the efficacy and tolerability of Proteoglycan F in patients with primary knee OA.Design: A 24-week randomized, placebo-controlled, double-blind clinical trial with two arms: (1) Proteoglycan F (received 10 mg proteoglycan daily, for 24 weeks) and (2) control group (received placebo). Knee symptoms and joint cartilage status (evaluated by ultrasound and MRI of knee joints), quality of life, serum cytokine levels (IL-1β and TNF-α), and safety evaluation were measured before, during, and after the treatment. Results: After 24-week treatment, pain reduction (in the KOOS pain score) of at least 20% and at least 50% (NRS scale) compared to baseline in the PGF group was significantly higher than those in the control group. The PGF group had greater reductions in the total scores of subchondral bone marrow edema, and bone cocoon under cartilage on knee MRI (classification according to WORMs), which were −2.27 (-4.0; −0.51) and −1.77 (-3.08; −0.46), respectively (p
- Published
- 2024
- Full Text
- View/download PDF